Menu
Currency
GWAS Study

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B et al.

26077951 PubMed ID
GWAS Study Type
3987 Participants
84 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KN
Kouri N
RO
Ross OA
DB
Dombroski B
YC
Younkin CS
SD
Serie DJ
SA
Soto-Ortolaza A
BM
Baker M
FN
Finch NCA
YH
Yoon H
KJ
Kim J
FS
Fujioka S
MC
McLean CA
GB
Ghetti B
SS
Spina S
CL
Cantwell LB
FM
Farlow MR
GJ
Grafman J
HE
Huey ED
RH
Ryung Han M
BS
Beecher S
GE
Geller ET
KH
Kretzschmar HA
RS
Roeber S
GM
Gearing M
JJ
Juncos JL
VJ
Vonsattel JPG
VD
Van Deerlin VM
GM
Grossman M
HH
Hurtig HI
GR
Gross RG
AS
Arnold SE
TJ
Trojanowski JQ
LV
Lee VM
WG
Wenning GK
WC
White CL
HG
Höglinger GU
MU
Müller U
DB
Devlin B
GL
Golbe LI
CJ
Crook J
PJ
Parisi JE
BB
Boeve BF
JK
Josephs KA
WZ
Wszolek ZK
UR
Uitti RJ
GN
Graff-Radford NR
LI
Litvan I
YS
Younkin SG
WL
Wang LS
EN
Ertekin-Taner N
RR
Rademakers R
HH
Hakonarsen H
SG
Schellenberg GD
DD
Dickson DW
Chapter II

Abstract

Summary of the research findings

Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10(-12)), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10(-8)), and 2p22 at SOS1 (rs963731; P=1.76 × 10(-7)). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10(-7)) and MAPT H1c (17q21; rs242557; P=7.91 × 10(-6)). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).

152 cases, 3,111 controls

Chapter III

Study Statistics

Key metrics and study information

3987
Total Participants
GWAS
Study Type
Yes
Replicated
67 cases, 457 controls
Replication Participants
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.